ADAPTIMMUNE THERAPEUTICS PLC
Cash Flow Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-70.8M | $-113.9M | $-165.5M | $-158.1M | $-130.1M | $-137.2M | $-95.5M | $-70.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $10.8M | $9.5M | $5.3M | $5.6M | $6.6M | $7.2M | $7.2M | $5.0M |
| Amortization | $411.0K | $387.0K | $809.0K | $937.0K | $967.0K | $838.0K | $622.0K | $391.0K |
| Stock-Based Compensation | $12.1M | $11.8M | $18.2M | $20.6M | $10.4M | $11.1M | $16.2M | $10.8M |
| Net Cash from Operating Activities | $-73.2M | $-140.9M | $-141.8M | $10.7M | $-53.6M | $-112.5M | $-104.4M | $-54.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $886.0K | $4.7M | $29.5M | $8.6M | $2.3M | $1.6M | $3.9M | $24.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-59.0M | $176.5M | $89.1M | $75.8M | $-278.9M | $94.9M | $-17.5M | $-126.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $78.7M | $880.0K | $12.9M | $3.3M | $340.1M | $366.0K | $102.7M | $103.6M |
| Net Change in Cash | $-53.8M | $37.4M | $-42.1M | $90.2M | $6.6M | $-17.6M | $-15.8M | $-74.5M |
| Free Cash Flow | $-74.1M | $-145.6M | $-171.3M | $2.2M | $-55.9M | $-114.1M | $-108.3M | $-79.0M |